Associated tags: Polymer, Fermentation, Biotechnology, Electronics, EPS, Plastic, Kaneka Corporation, Health, Research, COVID-19, Corporation, Manufacturing, Pharmaceutical, Infection, Kaneka, GMP, DNA, Other Manufacturing, FDA
Locations: UNITED STATES, NEW YORK, NORTH AMERICA, ASIA PACIFIC, EUROPE, JAPAN, TOKYO, TAIWAN, BELGIUM
Recycling,
Sustainability,
Consumer Electronics,
Technology,
Other Manufacturing,
Environment,
Other Transport,
Packaging,
Green Technology,
Chemicals,
Plastics,
Transport,
Logistics,
Supply Chain Management,
Manufacturing,
Corporation,
Kaneka,
Seawater,
Water,
Sony,
Television,
Petroleum,
Plastic,
Soil,
BRAVIA,
Multimedia,
CO2,
Kaneka Corporation Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii; hereinafter "Kaneka")(TOKYO:4118) has announced that its "Green Planet foam molded product" using KANEKA Biodegradable Polymer Green PlanetTM (hereinafter "Green Planet") has been adopted by Sony Corporation (Headquarters: Minato-ku, Tokyo; hereinafter "Sony") as a cushioning material for its large-screen televisions.
Key Points:
- Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Kazuhiko Fujii; hereinafter "Kaneka")(TOKYO:4118) has announced that its "Green Planet foam molded product" using KANEKA Biodegradable Polymer Green PlanetTM (hereinafter "Green Planet") has been adopted by Sony Corporation (Headquarters: Minato-ku, Tokyo; hereinafter "Sony") as a cushioning material for its large-screen televisions.
- To ensure shock resistance for large, heavy televisions during transportation, a certain level of strength and durability is required.
- Using Sony's technical expertise in packaging design and Kaneka's material molding technology, the two companies conducted a series of technical verifications to realize the use of Green Planet's foam molded product as cushioning materials.
- This is a world first*2 for Green Planet foam molded products to be used as cushioning materials for home electric appliances.
Retrieved on:
Wednesday, December 6, 2023
Surgery,
Medical Devices,
Health,
Cardiology,
Medical Supplies,
Atherosclerosis,
Human body,
Restenosis,
Kaneka,
Research,
Biliary tract,
Artery,
Extremities,
Esophagus,
Metal,
Sirolimus,
Coronary artery disease,
Risk,
Corporation,
Multimedia,
FIH,
Duodenum,
Thrombosis,
Blood,
Human,
Trachea,
Kaneka Corporation,
Pharmaceutical industry Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has acquired all shares of Japan Medical Device Technology Co., Ltd. (Headquarters: Kamimashiki-gun, Kumamoto; President: Shuzo Yamashita) (hereinafter JMDT), a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary.
Key Points:
- Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has acquired all shares of Japan Medical Device Technology Co., Ltd. (Headquarters: Kamimashiki-gun, Kumamoto; President: Shuzo Yamashita) (hereinafter JMDT), a developer and manufacturer of medical devices, on November 30, 2023, and made it a wholly owned subsidiary.
- In particular, stenting*1 for the treatment of coronary artery diseases such as atherosclerosis has a market worth 30 billion yen in Japan, and Kaneka is aiming to expand its business in this area.
- It is a medical device that widens tubular parts of the human body (blood vessels, trachea, esophagus, duodenum, colon, biliary tract, etc.)
- [Japan Medical Device Technology Co., Ltd.]
TOKYO, Oct. 9, 2023 /PRNewswire/ -- On October 5, 2023, Kaneka Corporation filed a lawsuit in the United States District Court for the Eastern District of New York against Cocrystal Technology Co. Ltd. and Cocrystal Health Industry Co. Ltd. (collectively "CoCrystal") seeking an injunction and monetary damages for CoCrystal's infringement of Kaneka's U.S. Patent No.
Key Points:
- TOKYO, Oct. 9, 2023 /PRNewswire/ -- On October 5, 2023, Kaneka Corporation filed a lawsuit in the United States District Court for the Eastern District of New York against Cocrystal Technology Co. Ltd. and Cocrystal Health Industry Co. Ltd. (collectively "CoCrystal") seeking an injunction and monetary damages for CoCrystal's infringement of Kaneka's U.S. Patent No.
- Kaneka asserts that CoCrystal uses Kaneka's patented production process to manufacture Crystal QH (the "Accused Product") in China, and then sells or offers to sell the Accused Product in the United States.
- In the forthcoming lawsuit against CoCrystal, Kaneka is fully prepared to assertively enforce its patent rights to the fullest extent.
- This may involve taking legal action against these customers, which could include adding them as additional defendants in the lawsuit against CoCrystal or initiating separate legal proceedings to address their patent infringement.
TOKYO, Oct. 9, 2023 /PRNewswire/ -- On October 5, 2023, Kaneka Corporation filed a lawsuit in the United States District Court for the Eastern District of New York against Cocrystal Technology Co. Ltd. and Cocrystal Health Industry Co. Ltd. (collectively "CoCrystal") seeking an injunction and monetary damages for CoCrystal's infringement of Kaneka's U.S. Patent No.
Key Points:
- TOKYO, Oct. 9, 2023 /PRNewswire/ -- On October 5, 2023, Kaneka Corporation filed a lawsuit in the United States District Court for the Eastern District of New York against Cocrystal Technology Co. Ltd. and Cocrystal Health Industry Co. Ltd. (collectively "CoCrystal") seeking an injunction and monetary damages for CoCrystal's infringement of Kaneka's U.S. Patent No.
- Kaneka asserts that CoCrystal uses Kaneka's patented production process to manufacture Crystal QH (the "Accused Product") in China, and then sells or offers to sell the Accused Product in the United States.
- In the forthcoming lawsuit against CoCrystal, Kaneka is fully prepared to assertively enforce its patent rights to the fullest extent.
- This may involve taking legal action against these customers, which could include adding them as additional defendants in the lawsuit against CoCrystal or initiating separate legal proceedings to address their patent infringement.
Software,
Research,
Other Natural Resources,
Data Management,
Recycling,
Technology,
Natural Resources,
Environment,
Other Manufacturing,
Green Technology,
Science,
Manufacturing,
Carbon,
Kaneka Corporation,
Dionysus,
JGC,
NEDO,
Breeding,
Engineering,
Gas,
Construction,
EPC,
Ministry of Economy, Trade and Industry,
Kobe City University of Foreign Studies,
Fermentation,
Multimedia,
O2,
Carbon neutrality,
Strategic Innovation Fund,
New energy,
Ministry,
Digital technology,
JGC Holdings Corporation,
Data analysis,
Corporation,
New Energy and Industrial Technology Development Organization,
Knowledge,
R,
Robotics,
CO2,
Agriculture,
Hyōgo Prefecture,
H2,
Shimadzu,
Green Planet During the project period (FY2023 to FY2030), the following three themes will be addressed.
Key Points:
- During the project period (FY2023 to FY2030), the following three themes will be addressed.
- Development and demonstration of production technology using microorganisms capable of producing substances from CO2 (Kaneka, JGC HD, Shimadzu)
Kaneka is the first company in the world to successfully commercialize KANEKA Biodegradable Polymer Green PlanetTM ("Green Planet"), which is produced by microorganisms from vegetable oil and other raw materials.
- Bacchus aims to drastically shorten the breeding time of smart cells*3 by upgrading the breeding platform consolidating its proprietary technologies.
- By utilizing its own digital technology, Bacchus will design cells optimized for gas fermentation and create a variety of species.
Retrieved on:
Thursday, January 19, 2023
Biotechnology,
Pharmaceutical,
Other Manufacturing,
Health,
COVID-19,
Infectious Diseases,
Genetics,
Manufacturing,
Food and Drug Administration,
Kaneka Corporation,
Nucleotide,
RNA transfection,
Organic acid,
DNA,
Corporation,
Animal,
FDA,
Bacteria,
Vaccine,
Infection,
Protein,
Cell division,
Growth,
Therapy,
Escherichia coli,
A-DNA,
RNA,
JPY,
Research,
Cancer,
Good manufacturing practice,
CDMO,
Cosmetics,
Health care,
Peptide,
Multimedia,
Good,
GMP,
Fine chemical Kaneka Eurogentec S.A. will grow as a leading company of biopharmaceutical CDMO*3, responding to the vigorous global demand for mRNA.
Key Points:
- Kaneka Eurogentec S.A. will grow as a leading company of biopharmaceutical CDMO*3, responding to the vigorous global demand for mRNA.
- The demand for GMP manufacturing of mRNA will increase drastically with the active development of biopharmaceutical pipelines by pharmaceutical companies worldwide.
- Kaneka Eurogentec S.A. is a CDMO for biopharmaceuticals inspected by the US FDA*4 and has world-class technology for producing plasmid DNA*5 and GMP manufacturing track records of over 25 years.
- In addition, Kaneka Eurogentec S.A. has started GMP manufacturing services for mRNA since 2020, and this capacity expansion will be utilized to expand the CDMO business.
Retrieved on:
Tuesday, November 29, 2022
Chemicals,
Plastics,
Health,
Infectious Diseases,
Manufacturing,
COVID-19,
Pharmaceutical,
Kaneka Corporation,
COVID-19,
Good manufacturing practice,
Food and Drug Administration,
Food,
DNA,
Ministry of Health and Medical Education,
Ministry,
Transport,
Tablet,
PCR,
GMP,
Infection,
Corporation,
Chūō-ku,
Ministry of Health, Labour and Welfare,
Pharmaceutical industry,
Health,
Shionogi Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) will manufacture and supply intermediates to Shionogi & Co., Ltd. (Headquarters: Chuo-ku, Osaka; Chief Executive Officer: Isao Teshirogi, Ph.D.) for use in Xocova*1 (Ensitrelvir Fumaric Acid) Tablets 125mg, a drug for the treatment of SARS-Cov-2 infection.
Key Points:
- Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) will manufacture and supply intermediates to Shionogi & Co., Ltd. (Headquarters: Chuo-ku, Osaka; Chief Executive Officer: Isao Teshirogi, Ph.D.) for use in Xocova*1 (Ensitrelvir Fumaric Acid) Tablets 125mg, a drug for the treatment of SARS-Cov-2 infection.
- Shionogi recognized Kaneka for its long years of experience in manufacturing raw materials for medicines, and selected Kaneka as its main supplier for the drug's intermediates, which require GMP*2 management.
- The two companies have worked closely together for clinical development, approval application, and establishment of mass production supply chain.
- Kaneka will continue to improve its manufacturing systems and provide Shionogi with a stable supply of intermediates, playing a vital role in Shionogi's commercial supply chain.
Retrieved on:
Tuesday, February 22, 2022
FDA,
Chemicals,
Plastics,
Manufacturing,
Other Health,
Pharmaceutical,
Medical Devices,
Hospitals,
Genetics,
Clinical Trials,
Other Manufacturing,
Biotechnology,
Science,
Other Science,
Research,
Health,
Medical Supplies,
IVT,
Oligonucleotide,
GMP,
Health,
Proteomics,
RNA transfection,
A-DNA,
Method,
Quality control,
Kaneka Corporation,
COVID-19,
Contract,
Fermentation,
CDMO,
Electronics,
EPS,
Plastic,
Genomics,
Vaccine,
Multimedia,
DNA,
Biotechnology,
Infection,
FDA,
Polymer,
Patient,
Technology,
CEO,
Research,
HIV,
Eurogentec,
mRNA,
Kaneka Eurogentec,
Kaneka Corporation,
MRNA,
KANEKA EUROGENTEC,
KANEKA CORPORATION In this project Eurogentec successfully produced and purified 25 g of material in one batch that will be tested by the customer.
Key Points:
- In this project Eurogentec successfully produced and purified 25 g of material in one batch that will be tested by the customer.
- Ingrid Dheur, Vice President Biopharma Development at Kaneka Eurogentec stated, This successful production confirms our ability to produce mRNA at large scale and with a quantity and purity level that exceeds the targets requested by the customer.
- Lieven Janssens, President and CEO at Kaneka Eurogentec added The rapid growth in cell and gene therapy products is driving the need for plasmid DNA and mRNA production.
- In 2010, Eurogentec, renamed Kaneka Eurogentec in April 2017, became part of Kaneka Corporation, a large Japanese chemical company focusing on technology and innovation.
Retrieved on:
Tuesday, February 8, 2022
Policy,
Soil,
Biophysical environment,
Horticultural oil,
Polyhydroxyalkanoates,
Technology,
ESG,
Plastic,
Product life-cycle theory,
Water,
Wellness,
Minato,
Recycling,
Renewable energy,
Green Planet,
Social,
Kaneka Corporation MINATO-KU, Tokyo, Feb. 8, 2022 /PRNewswire/ --Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) is pleased to announce that it will significantly increase production capacity for KANEKA Biodegradable Polymer Green Planet (referred to below as "Green Planet") in Japan.
Key Points:
- MINATO-KU, Tokyo, Feb. 8, 2022 /PRNewswire/ --Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka) is pleased to announce that it will significantly increase production capacity for KANEKA Biodegradable Polymer Green Planet (referred to below as "Green Planet") in Japan.
- Green Planet resins and compounds break down in both soil and water at the end of life depending on environmental conditions.
- Green Planet compounds are already being used to make straws, cutlery, coffee capsules, bags, films and other applications.
- Green Planet can be used in a wide variety of applications, and this range is expected to grow even further in the future.
Retrieved on:
Wednesday, February 17, 2021
Medical Supplies,
Health,
Infectious diseases,
Research,
Science,
Pharmaceutical,
Biotechnology,
Branches of biology,
Biology,
Biochemistry,
RNA,
Molecular biology,
Eurogentec,
LIEGE,
Seraing,
Kaneka Corporation,
Plasmid,
Messenger RNA,
Kaneka Eurogentec,
Kaneka Corporation Dr. Lieven Janssens, Kaneka Eurogentecs President and CEO, said, Manufacturing GMP mRNA complements perfectly our ongoing GMP DNA manufacturing activities providing a one-stop-shop offering Plasmid DNA, linearization and mRNA production.
Key Points:
- Dr. Lieven Janssens, Kaneka Eurogentecs President and CEO, said, Manufacturing GMP mRNA complements perfectly our ongoing GMP DNA manufacturing activities providing a one-stop-shop offering Plasmid DNA, linearization and mRNA production.
- Its definitely the ambition of Kaneka Eurogentec to become the world leading CDMO for mRNA, as we are already for the production of plasmid DNA..
- The expertise of the company for more than 25 years as CDMO for the manufacturing of GMP Biopharmaceuticals is recognized worldwide.
- Kaneka Eurogentec contributes to improving health and fighting diseases by supplying products and services to scientists involved in life science research, molecular diagnostics, and therapeutic developments.
